valproic acid has been researched along with Cardiomegaly in 5 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Cardiomegaly: Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Another set of rats were treated with hydralazine (25 mg/kg per day orally) to determine the pressure-independent effects of HDAC inhibition on hypertension." | 3.76 | HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive rats. ( Cardinale, JP; Elks, CM; Francis, J; Guggilam, A; Mariappan, N; Pariaut, R; Sriramula, S, 2010) |
| "Valproic acid has been shown to upregulate estrogen receptors (ERs) in breast and prostate cancer tissues." | 1.48 | Magnesium valproate ameliorates type 1 diabetes and cardiomyopathy in diabetic rats through estrogen receptors. ( Bhadada, S; Dudhrejiya, A; Patel, B; Rabadiya, S; Vaishnav, D, 2018) |
| "The regulatory paradigm in cardiac hypertrophy involves alterations in gene expression that is mediated by chromatin remodeling." | 1.46 | Selective inhibition of HDAC2 by magnesium valproate attenuates cardiac hypertrophy. ( Goyal, RK; Patel, BM; Raghunathan, S, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rabadiya, S | 1 |
| Bhadada, S | 1 |
| Dudhrejiya, A | 1 |
| Vaishnav, D | 1 |
| Patel, B | 1 |
| Kee, HJ | 1 |
| Bae, EH | 1 |
| Park, S | 1 |
| Lee, KE | 1 |
| Suh, SH | 1 |
| Kim, SW | 1 |
| Jeong, MH | 1 |
| Raghunathan, S | 1 |
| Goyal, RK | 1 |
| Patel, BM | 1 |
| Cardinale, JP | 1 |
| Sriramula, S | 1 |
| Pariaut, R | 1 |
| Guggilam, A | 1 |
| Mariappan, N | 1 |
| Elks, CM | 1 |
| Francis, J | 1 |
| Lee, TM | 1 |
| Lin, MS | 1 |
| Chang, NC | 1 |
5 other studies available for valproic acid and Cardiomegaly
| Article | Year |
|---|---|
Magnesium valproate ameliorates type 1 diabetes and cardiomyopathy in diabetic rats through estrogen receptors.
Topics: Animals; Cardiomegaly; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Cardiomy | 2018 |
HDAC inhibition suppresses cardiac hypertrophy and fibrosis in DOCA-salt hypertensive rats via regulation of HDAC6/HDAC8 enzyme activity.
Topics: Animals; Cardiomegaly; Desoxycorticosterone Acetate; Disease Models, Animal; Enzyme Activation; Fibr | 2013 |
Selective inhibition of HDAC2 by magnesium valproate attenuates cardiac hypertrophy.
Topics: Animals; Biomarkers; Cardiomegaly; Disease Models, Animal; DNA, Mitochondrial; Down-Regulation; Fema | 2017 |
HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Cardiomegaly; Echocardiography; Histone Deacetylas | 2010 |
Inhibition of histone deacetylase on ventricular remodeling in infarcted rats.
Topics: Animals; Atrial Natriuretic Factor; Blotting, Western; Cardiomegaly; Cell Size; Collagen; Coronary V | 2007 |